25I-NB3OMe (2C-I-NB3OMe, NB3OMe-2C-I) is a phenethylamine hallucinogen which acts as a partial agonist for the human 5-HT2A receptor.[1] It is a derivative of 2C-I.
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C18H22INO3 |
| Molar mass | 427.282 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Legality
editUnited Kingdom
editThis substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.[2]
United States
edit25I-NB3OMe is not explicitly listed as a controlled substance in the United States, but is a positional isomer of 25I-NBOMe[3] and thus may be considered a Schedule I drug under the Federal Analogue Act, meaning that it would be subject to the same penalties for possession, distribution, and manufacture as 25I-NBOMe.
References
edit- ^ Hansen M, Phonekeo K, Paine JS, Leth-Petersen S, Begtrup M, Bräuner-Osborne H, Kristensen JL (March 2014). "Synthesis and structure-activity relationships of N-benzyl phenethylamines as 5-HT2A/2C agonists". ACS Chemical Neuroscience. 5 (3): 243–249. doi:10.1021/cn400216u. PMC 3963123. PMID 24397362.
- ^ "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014". UK Statutory Instruments 2014 No. 1106. www.legislation.gov.uk.
- ^ Casale JF, Hays PA (2012). "Characterization of Eleven 2,5-Dimethoxy-N-(2-methoxybenzyl)phenethylamine (NBOMe) Derivatives and Differentiation from their 3- and 4-Methoxybenzyl Analogues - Part I". Microgram Journal. 9 (2): 84–109.